Transcriptomic Analysis of the Effects of a Fish Oil Enriched Diet on Murine Brains

Rasha Hammamieh*, Nabarun Chakraborty, Aarti Gautam, Stacy-Ann Miller, Seid Muhie, James Meyerhoff, Marti Jett

United States Army Center for Environmental Health Research, Fort Detrick, Maryland, United States of America

Abstract

The health benefits of fish oil enriched with high omega-3 polyunsaturated fatty acids (n-3 PUFAs) are widely documented. Fish oil as dietary supplements, however, show moderate clinical efficacy, highlighting an immediate scope of systematic in vitro feedback. Our transcriptomic study was designed to investigate the genomic shift of murine brains fed on fish oil enriched diets. A customized fish oil enriched diet (FD) and standard lab diet (SD) were separately administered to two randomly chosen populations of C57BL/6J mice from their weaning age until late adolescence. Statistical analysis mined 1,142 genes of interest (GOI) differentially altered in the hemibrains collected from the FD- and SD-fed mice at the age of five months. The majority of identified GOI (~40%) encodes proteins located in the plasma membrane, suggesting that fish oil primarily facilitated the membrane-oriented biofunctions. FD potentially augmented the nervous system’s development and functions by selectively stimulating the Src-mediated calcium-induced growth cascade and the downstream PI3K-AKT-PP1 pathways. FD reduced the amyloid burden, attenuated oxidative stress, and assisted in somatostatin activation—the signatures of attenuation of Alzheimer’s disease, Parkinson’s disease, and affective disorder. FD induced elevation of FKBP5 and suppression of BDNF, which are often linked with the improvement of anxiety disorder, depression, and post-traumatic stress disorder. Hence we anticipate efficacy of FD in treating illnesses such as depression that are typically triggered by the hypoxiaactivities of dopaminergic, adrenergic, cholinergic, and GABAergic networks. Contrastingly, FD’s efficacy could be compromised in treating illnesses such as bipolar disorder and schizophrenia, which are triggered by hyperactivities of the same set of neuromodulators. A more comprehensive investigation is recommended to elucidate the implications of fish oil on disease pathomechanisms, and the result-driven repositioning of fish oil utilization may revitalize its therapeutic efficacy.

Introduction

Fish oils, derived from cold water oily fish like albacore tuna and salmon, are high in omega-3 polyunsaturated fatty acids (n-3 PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are believed to have many health benefits [1–3]. N-3 PUFAs and fish oil, the major dietary source of n-3 PUFA, have been extensively studied as dietary supplements suggesting beneficial effects for the treatment of inflammation [4–6], macular degeneration [7,8], Alzheimer’s disease (AD) [9,10], Parkinson’s disease (PD) [11–13] depression [6,13,14] and anxiety disorders [6,15]. Optimum maintenance of the synaptosome, brain cell functions, and general health of human central nervous system are potentially facilitated by n-3 PUFA [16–18].

Despite the wide implications of n-3 PUFA on the brain functions, clinical efforts investigating the efficacy of n-3 PUFAs and in that matter, the fish oil as dietary supplements for the treatment of psychiatric diseases have yet met with mixed results. Two separate clinical trials on Alzheimer’s patients and Parkinson’s patients supplemented by n-3 PUFA enriched diets failed to deliver a robust outcome. The trials found n-3 PUFA effective only if it was administered during the early onset of the AD [10]; in treating PD, its efficacy was restricted to mitigating the depression syndrome only [12]. N-3 PUFAs demonstrated significant positive impact on the major depressive episodes with anxiety co-morbidity [6,13]; however, the supplement’s efficacy on the heterogeneous disease profile (with and without comorbid anxiety) was marginal [13]. A pilot trial offering n-3 PUFA supplementation to patients immediately after life-threatening incidents resulted in reduced post traumatic syndromes [19].

A number of clinical, epidemiological, and laboratory studies linked the health benefits of n-3 PUFA to various dietary compositions, including EPA alone [20,21], the EPA:DHA ratio [22], the arachidonic acid (AA):EPA ratio [23,24] the AA: alpha-linolenic acid (ALA) ratio [25] and the overall n-3 PUFA; n-6 PUFA ratio [26]. Consequently, the appropriate dietary composition is still a subject of ongoing investigation.

Researchers have been using rodent models for decades to evaluate the efficacy of fish oil as the dietary supplement. Justifying the model, studies reported the increased levels of EPA and DHA accompanied by decreased AA in the brain tissues of rats fed on fish oil enriched diets [27,28]. The n-3 PUFA enriched diet helped...
balancing behavioral plasticity [29], improved cognitive function [9] and working memory [30], enhanced neuroprotection [31,32] and reduced anxiety and depression-like traits [33,34] in vitro. High throughput genomic studies evaluating the effects of fish oil on the rodent brain identified genes involved in ion channels, neuronal function, signal transduction, synaptic plasticity, cytoskeleton and membrane association, and energy metabolism [35–41].

The comprehension of the underlying molecular mechanism is potentially critical to understand the effect of the fish oil on neuronal activities. Toward this goal, we studied the effects of high dietary intake of fish oil on the genomic regulations in the mouse brain, and characterized the potentially associated molecular events focused on the nervous system and neurofunctions. The effects of FD on the genes relevant to neurogenesis are of particular interest in the context of the recent study manifesting n-3PUFA as the mediators in generating new neuronal cells [42].

Materials and Methods

2.1 Ethics statement
Research was conducted in compliance with the Animal Welfare Act, and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals (NRC 2011) in facilities that are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International. The protocol was approved by the IACUC committee of Walter Reed Army Institute of Research, Silver Spring, MD.

2.2 Diet types and mouse handling
The percentage of the fish oil in the customized FD was restricted to 16% to maintain the food pellet structure consistent with that of SD (Certified Rodent Diet 5002*, Purina LabDiet, MA). Thus, the external appearance and texture of FD and SD appeared similar. Solid food pellets helped maintaining the tidiness of the cages; hence, the cages occupied by FD- or SD-fed mice followed the same schedule of regular lab handling, precluding any concerns associated with psychological bias due to the handling with variable frequency [43]. Possible bias due to the rodents’ potential favoring of particular food textures was further averted by introducing the two diets with similar textures.

### Table 1. Compositions of the primary nutrients and n-3 PUFA and n-6 PUFA in two diets of interest.

|                     | Fish diet (FD) | Standard diet (SD) |
|---------------------|---------------|--------------------|
|                     | % by weight  | % kcal            | % by weight  | % kcal            |
| Primary Nutrients    |               |                    |               |                   |
| Protein             | 18.3         | 17.2              | 23.9         | 24.11             |
| Carbohydrate        | 51.8         | 48.8              | 53.8         | 62.67             |
| Fat                 | 16.0         | 33.9              | 5.7          | 13.22             |
| Kcal/g              | 4.2          |                    | 4.07         |                   |
| Polysaturated Fatty Acids |      |                    |               |                   |
| n-3 PUFA            |              |                    |               |                   |
| EPA                 | 2.56         |                   | 0.20         |                   |
| DHA                 | 1.73         |                   |             |                   |
| ALA                 | 0.29         |                   |             |                   |
| n-6 PUFA            |              |                    |               |                   |
| LA                  | 0.29         |                   | 1.22         |                   |
| AA                  | 0.37         |                   | <0.01        |                   |
| n-3 PUFA:n-6 PUFA   | 7:1          |                   | 1:6          |                   |
| EPA:DHA             | 1.5:1        |                   |             |                   |

The composition of protein, carbohydrate, and fat present in the fish oil enriched diet (FD) and standard diet (SD). The percent fraction by the weight and the calories offered by each diet type is presented. Total calories (Kcal/g) offered by each diet type is noted. The percentage fractions of three n-3 PUFA (EPA, DHA, and ALA) and two n-6 PUFA (AA and LA) are reported.
doi:10.1371/journal.pone.0090425.t001

Figure 1. Cluster view (heatmap) of 1,142 genes differentially expressed between the mice fed with fish oil enriched diet (FD) vs. standard lab diet (SD). These genes are identified using a cut-off of ±1.5 fold changes between the mice with FD vs. SD, with FDR<0.05, and clustered using Pearson correlation algorithm. The color scale of the fold change (log1.5 (FD-/SD-fed mice) is noted at the bottom right of the figure. The first three columns from left represent the genomic expressions of 4 animals fed on FD and subsequent three columns of 3 animals fed on SD.
doi:10.1371/journal.pone.0090425.g001
Table 2. A brief literature survey of clinical studies associated with the panel of genes validated by qPCR.

| Gene Name | Trauma | Cohort | Major findings | Reference |
|-----------|--------|--------|----------------|-----------|
| NOS-1     | Depression | Snap-frozen and paraffin-embedded tissue of anterior cingulate cortex from Caucasian subjects; major depressive disorder, N = 5; bipolar disorder, N = 7; and control N = 12 | Diminished NOS1 in anterior cingulate cortex with depression, possibly by affecting glutamatergic and GABAergic neurotransmission | [120] |
| AD        | European subjects; AD (baseline, N = 19; 30 months follow-up, N = 95; 60 months follow-up, N = 106) and controls (baseline, N = 555; 30 months follow-up, N = 360; 60 months follow-up, N = 285) | Decreased NOS1 expression in concert with degeneration of NOS-I neurons likely results in impaired hippocampal nitricergic neurotransmission. | [121] |
| Schizophrenia | Japanese patient; Postmortem brain samples of 12 schizophrenic patients, N = 12; and control, N = 15 | Decreased NOS-1 is associated with schizophrenia patients; with stronger correlation for female patient | [122] |
| Schizophrenia/ Bi-polar disorder | Post mortem brain samples from schizophrenic patients N = 26; bipolar patients N = 30; and controls, N = 29 | Over-expression of specific NOS1 isoforms among the schizophrenia patients, but not among bipolar patients | [123] |
| MMP9 | Traumatic brain injury (TBI) | TBI patient, N = 7; and control, N = 4; all male | Increased levels of MMP-9/3 in the ventricular CSF of patients with severe TBI. | [124] |
| Bipolar depression | Patients with bipolar disorder (N = 54); and controls (N = 29) | Increased serum MMP-9 during depression in young patients | [125] |
| AD | AD patients (N = 38); and controls (N = 34) | Higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals. | [126] |
| AD/PD | AD patients (N = 30); PD patients (N = 24); and controls (N = 32) | Elevated MMP-9 in the plasma of AD patients; but no significant changes of MMP-9 levels in PD cohorts. | [127] |
| Schizophrenia | Schizophrenic patients (N = 442); and controls (N = 558) | Significant preponderance of −1562 C.T polymorphism in patients | [128] |
| SOD-1 | AD | Post-mortem brain samples from AD patient, N = 4; and patients diagnosed with Huntington’s Disease, N = 4 | Decreased SOD-1 in AD patients’ hippocampus | [129] |
| Down syndrome (DS) and AD | Post-mortem brain samples; DS, N = 9, AD, N = 9; and controls, N = 9 | Increased SOD-1 in DS temporal, parietal, and occipital cortex, whereas decreased SOD-1 in the AD temporal cortex | [130] |
| BDNF | PTSD | All women cohort, diagnosed with PTSD, N = 17; with PTSD+ childhood physical neglect, N = 17; controls, N = 15 | Lower plasma BDNF in association with PTSD, and more strongly linked with childhood neglect driven PTSD | [131] |
| PTSD | Patients with history of trauma, N = 34; and controls, N = 34 | Higher level of serum BDNF levels right after the traumatic events decreasing over time | [84] |
| Bipolar disorder | UK Caucasian subjects, BD, N = 962; and control, N = 2100 | No overall influence from the Val66Met polymorphism of BDNF, with a moderate association with the susceptibility to the rapid-cycling subset of the disorder. | [132] |
| Major depression | Korean subjects, major depression, N = 310 and controls, N = 209 | Significant association of BDNF with the disease onset among the younger subgroup only | [133] |
| PD | PD patients, N = 453 and controls, N = 291 | Increased PD risk in association with the pesticide exposure | [134] |
| AD | AD patients with rapid cognitive decline, N = 12; and slow cognitive decline, N = 28 | Decreased BDNF serum levels in AD patients with fast cognitive decline | [135] |
| FKBPS | PTSD | Nonpsychiatric clinic patients with significant levels of childhood abuse and non-child abuse trauma, N = 900 | High interaction between four SNPs of the FKBPS gene (rs9296158, rs3800373, rs1360780, and rs9470080) with severity of child abuse as a predictor of adult PTSD | [136] |
| PTSD | Subjects linkage and association studies of the genetics of cocaine, opioid, and alcohol dependence, and controls; N = 1146 European Americans (EAs) and 1284 African Americans (AAs) | AA subjects: Significant association between one SNP (rs9470080) with childhood abuse eliciting PTSD. EA subjects: Significant association of PTSD risk with alcohol dependence and childhood adverse experiences interacting with FKBPS polymorphisms | [137] |
| Anxiety/depression | Patients, newly diagnosed with advanced gastric cancer and supposed to receive first-line chemotherapy, N = 130; and control similar patients after two cycles of chemotherapy, N = 93 | Significant association of anxiety with FKBPS rs9296158, and marginal association with rs9470080 and rs1360780. Marginal association of depression with FKBPS rs9470080 and rs9296158 | [138] |
| Major depression | Patients diagnosed with major depression, N = 68; and controls, N = 87 | Significant interaction between disease status and FKBPS risk allele carrier status (minor allele T). | [139] |

Past clinical reports (demography of the cohorts and major findings) associated with five genes (NOS-1, MMP-9, SOD-1, BDNF and FKBPS) are reported. doi:10.1371/journal.pone.0090425.t002
Briefly, these two diets were similarly supplemented by proteins (FD: 18.3%, SD: 20.7%, both by weight), carbohydrates (FD: 53.8%, SD: 51.8%, both by weight) and crude fibers (FD: 4.5%, SD: 4.5%, both by weight); vitamins and minerals were also supplemented proportionately including vitamin E (FD: 16 IU/kg; SD: 65 IU/kg). The different supplements of fat (FD: 16%; SD: 5.5%, both by weight), primarily the higher n-3 PUFA supplements in FD (FD: 4.70%; SD: 0.20%, by weight) outlined the major difference between FD and SD. The n-6 PUFA supplements were marginally lower in FD (FD: 0.66%; SD: 1.22%, by weight). Overall caloric contributions from the two diets were comparable (FD: 4.2 Kcal/g; SD: 4.07 Kcal/g) (Table 1). To maintain the food quality across the study duration and to minimize the oxidative damage to n-3 PUFA, freshly prepared food was purchased every two months and stored at 4°C in sealed bags and the food chambers were replenished daily with fresh supplies.

In designing the assay, we refrained from adjusting any potential shortcomings of the fish oil. For instance FD diet contained 0.3% linoleic acid (LA), whose scale of representation in rodent diets has long been a subject of investigation [44,45]; of note the nearly equi-caloric control diet contained 1.22% LA (Table 1), as per the recommendation [44]. Hereby, our result highlighted the diet-induced molecular events potentially explaining the suggested benefits or the adverse effects of fish oil on the brain.

C57BL/6j male mice were purchased from Jackson Laboratory (Bar Harbor, ME) at the age of three weeks, singly housed and immediately introduced to either SD or FD. Mice had free access to their respective diets and standard lab-supplied liquids for next five months (~20 weeks).

### 2.3 Collection of hemibrains and RNA isolation

Following the euthanization of the mice by cervical dislocation the brains were removed from their crania. After the mid-sagittal section, the hemibrains were collected by a highly trained professional experienced with this procedure, who was kept blinded from the animal identities during the dissection period. The dissected brain sections were snap-frozen, saved in individually labeled tubes, and transferred to the freezer at the end of the day. The entire process starting with the brain removal from the skull to the snap-freezing of the last brain region took less than 20 minutes as described in our earlier report [46].

On the day of nucleic acid isolation, organs were weighed before thawing and the appropriate amounts of Trizol™ (Invitrogen, NY) were added. RNA was isolated from the Trizol™ suspensions as per the manufacturer’s guidelines. Briefly, the hemibrain was homogenized using the TissueLyser system (Qiagen, MD), phase separated with vigorous agitation, and the aqueous phase was collected. Serial alcohol-based precipitations and washes were performed on the aqueous phase to obtain RNA. The isolated nucleic acids were quantified and qualified using the Agilent BioAnalyzer as reported earlier [47].

### 2.4 High throughput transcriptomic expression analysis

The dual dye microarray was carried out using the Whole Mouse Genome Microarray Kit (Agilent Technologies, Inc.) following the vendor’s protocol. 200–2000 ng of purified RNA was labeled with Cy-5 dyes and the reference RNA (Agilent, CA) with Cy-3 dyes (N = 4 from FD-fed mice and N = 3 from SD-fed mice. One SD sample was misplaced). The samples were simultaneously hybridized to Agilent 4×44k slides (platform number: 14868) and incubated for 17 h at 55°C. After overnight hybridization, slides were processed in a series of washes. The slides were scanned using an Agilent DNA microarray scanner and the features were extracted using the default setting of the Feature Extraction software (Feature Extraction software v.10.7, Agilent, CA).

### 2.5 Data filtering and process normalization

GeneSpring v.10.1 (Agilent Technologies, Inc., CA) was used to carry out the preliminary data filtration and statistical analysis. Each chip was subjected to intra-chip normalization using the locally weighted scatter-plot smoothing method (LOWESS) [48]. Genes were identified that were differently expressed between the hemibrains of mice fed on FD vs. SD based on ±1.5 fold change cut-off with FDR<0.05.

The microarray data was submitted to the Gene Expression Omnibus (GEO). This can be searched using the Platform ID: GPL7202, Series: GSE46933.

### 2.6 Cluster and functional analysis

GeneSpring v.10.1 (Agilent Technologies, Inc., CA) was used to perform two-dimensional hierarchal clustering using Pearson correlation algorithm (Figure 1). For the gene ontological classification and enrichment analysis, FATIGO® [49], MSigDB-Parametric Geneset Enrichment analysis (http://www.broadinstitute.org/gsea/msigdb/index.jsp) and GeneCite [50] were used. Ingenuity Pathway Analysis (IPA; www.ingenuity.com) was used to mine the pathways and networks relevant to the present study.

### 2.7 Real-time PCR validation of microarray results

The mRNA microarray results were validated using two platforms. The high throughput real-time PCR was carried out using the RT² Profiler PCR Array System (SABiosciences, MD) on the ABI 7900HT platform (Life Technologies, CA). The PCR was carried out using three biological replicates for each diet. SDS 2.4 software supplied by ABI, CA, was used to compute the changes of threshold cycles (Ct) i.e., $2^{-\Delta \text{Ct}}$, where $\Delta \text{Ct} = \text{Ct} (\text{GOI}) - \text{mean} (\text{Ct} (\text{HKG}))$. GOI denotes the gene of interest, and HKG denotes the housekeeping gene. In order to eliminate the false positives, the mRNA reads were screened based on two criteria: (i) the controls’ threshold cycles were >30, and samples’ threshold cycles were <30 (or vice versa), and (ii) the $p$-values for the fold-changes were either unavailable or relatively high ($p>0.05$) from the assay backgrounds.

In addition, qPCR of five genes (NOS1, FKBP5, MPP9, SOD1 and BDNF) was carried out using primers purchased from Fisher Scientific, Inc, PA using their Solaris gene expression assay (Table S1). The selection of these genes is justified in a brief literature survey (Table 2). Real-time PCR was performed in the HT700 platform (Applied BioSystems, CA) using five technical replicates. The downstream analysis was conducted using the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and beta-actin housekeeping genes following the protocol described elsewhere [47].

## Results

The diet compositions listed in Table 1 revealed relatively comparable supplements of major nutrients and consumable calories derived from FD and SD. The major differences between the two diet types were attributed to the n-3 PUFA and n-6 PUFA supplements (Table 1).

The mice weighing 10–12 grams at the age of three weeks had a 61.2% increase in body weight as a result of consuming SD for five months, thus the average weight became 30.96 grams (% CV = 6.12). During the same five month period, FD-fed mice...
showed 67.2% increase in body weight; the average weight became 36.6 grams (CV = 13.17). It was a near significant difference in the change of body weights between the FD- vs. SD-fed mice, with the FD-fed group gaining 18% more in body mass (p = 0.06).

Transcriptomic analysis identified 1,142 genes altered between the mice fed on FD vs. SD (6.6% of total genes). The GOI demonstrated ±1.5 fold changes with FDR < 0.05. Figure 1 is a cluster view of these GOI generated using the Pearson correlation algorithm; 659 (58% of GOI) and 483 (42% of GOI) transcripts were elevated and suppressed by FD, respectively. One hundred and fifty two unknown genes with the remaining 900 known genes are documented in Table S2. Figure S1 shows a volcano plot of the same gene set. The entire list is available in the public domain: Gene Expression Omnibus (GEO) and this can be using the Platform ID: GPL7292, Series: GSE46933.

Meeting the objectives of the present study, subsequent convergent functional analysis identified the transcripts linked to the neurogenesis, neuroviability and neurodegenerative disorders.

3.1. Biofunction analysis
The 1,142 GOI enriched an ensemble of biofunctions. Table 3 reports the top-ranked biofunctions (p < 0.0001) that are enriched by at least 50 genes. The complete list of biofunctions is shown in the Table S3. We identified four biofunctions pertinent to the present objective: “Neurological disease”, “Nervous system development and function”, “Inflammatory response” and “Cell death”, and these were further classified into subcategories enriched by at least 30 genes. Of note, we found certain enriched pathways, such as “LPS/IL-1 Mediated Inhibition of RXR Function”, “Amyotrophic Lateral Sclerosis Signaling” and “Hepatic Fibrosis/Hepatic Stellate Cell Activation”; however, we failed to derive biologically meaningful information from these pathways. Therefore, we focused on exploring the four biofunctional modules identified herein. Together, these four biofunctions enlisted 247 genes (153 up- and 94 down-regulated by FD). The majority of the genes (99 genes, i.e. 40% of the 247 genes) encode the proteins that are located in the plasma membrane. Curating from the Allen Brain Atlas (mouse.brain-map.org) we linked the 20% of these 247 genes to possible brain regions (Table S4).

3.1.1. Neurological diseases. Two hundred and sixty genes (22.7% of GOI) were associated with the “neurological diseases” with a range of p values from 1.01 x 10^-3 to 5.96 x 10^-5 (Table 3). In particular, we focused on three diseases: (i) movement disorder (McD) (93 genes, p = 8.13 x 10^-7) (Figure 2A, Tables 3 and 4), (ii) AD (70 genes, p = 1.11 x 10^-5) (Figure 2B, Tables 3 and 4) and (iii) PD (50 genes, p = 1.26 x 10^-7) (Figure 2B, Tables 3 and 4). The movement disorder was the most enriched candidate on the list. We also selected AD and PD for further discussion in light of the suggested implications of n-3 PUFA s on these particular illnesses [9,10,12,51]. Together, these three diseases explained approximately 34% of the transcripts linked to “neurological diseases”, with 16 common genes among three disease types of interest. In addition, 3 transcripts were shared by McD and AD, and 14 transcripts by McD and PD.

FD elevated the expression of a substantial subset of transcripts associated with McD (76%), AD (58%) and PD (74%). Proteins associated with 45 transcripts representing 48% of McD associated genes are located in membranes; likewise, 42% (29 transcripts) and 54% (27 transcripts) of the proteins related to AD and PD, respectively, are located in the membranes.

A comprehensive FD-induced elevation was observed among the transcripts associated with the calcium and potassium channels (CACNA1A, CACNA1D, KCNMB3, KCNA5, KCNIP1, KCNC4, KCNC3, KCNA5, KCNj6, KCTD7 and KCNQ2) except one, namely CACNA1H. All transcriptomic members of solute carrier family (SLC18A5, SLC3A7 and SLC6A4), and dopamine, glutamate, adrenergic and cholinergic receptors (DRD3, GRID2, GRIN2A, GRM2, GRM7, ADRA1D, ADRB2, CHRNB3 and CHRNA5) were also elevated. Alternatively, FD reduced the expression of the transcripts associated with the cytokines (IL1B, IL10, PRL and TNF) and early growth response agents (EGR1 and EGR2). The members of zinc finger family (ZNF383B and ZNF425) displayed over expression, but those of the trash shirt zinc finger family (TSH2) and TSH2 demonstrated suppressed expression in the FD-fed mice. Transcripts encoding the G-protein coupled receptor (GPR6) were elevated, but that encoding the ionotropic GABA receptors were differentially expressed. FD inhibited the transcripts associated with the domain of alpha 5 (GABRA5) and elevated alpha 4 (GABRA4), respectively. Although GABRG3 and GABRA5 are phenotypically juxtaposed in human chromosome, FD elevated the former and suppressed the later transcript.

3.1.2. Nervous system development and function. One hundred and fifty genes (13.13% of GOI) were associated with the “nervous system development and function” with a range of p values from 2.92 x 10^-3 to 1.01 x 10^-7 (Table 5). Neurogenesis (Ngs) was the most enriched function; 73 transcripts represented 48.6% of all the members associated with the parent function term. Further investigation of Ngs associated genes identified five of the most significantly enriched functional sub-categories, which enlisted 62 genes representing 85% of all genes associated with Ngs. These sub-families were (i) differentiation of neurons (DoN) (30 genes, p = 1.7 x 10^-31) (Figure 3A, Table 5), (ii) growth of neurites (GoN) (29 genes, p = 2.3 x 10^-24) (Figure 3A, Table 5), (iii) differentiation of the nervous system (DNS) (29 genes, p = 7.6 x 10^-25) (Figure S2, Table 5), (iv) formation of plasma membrane projections (FMP) (26 genes, p = 4.71 x 10^-19) (Figure S2, Table 5) and (v) neurotogenesis (Ngs) (23 genes, p = 8.02 x 10^-16) (Figure S2, Table 5). Among these five closely interconnected sub-families, DoN and GoN collectively enlisted the largest number of unique transcripts (50, 68.5% of the genes associated with Ngs). Therefore, we focused primarily on these two functional sub- categories (Figure 3A).

DoN and GoN shared five transcripts: BMP6, CDK5R2, CNR1, NTRK3, and ATOH7; all of them were elevated by FD. In addition, there were four transcripts shared by all five sub-categories; NGFR was elevated, and FGFR2, HGF and MAPK3 were all suppressed by FD.

Synaptic transmission (SyT) (Figure 3B, Table 5) was a highly significant sub-family of nervous system development and function (34 molecules, 23.3% of parent function; p = 4.9 x 10^-7) sharing 10 common genes with Ngs (CNR1, SLC3, NGLN1, ADRB2, CACNA1A, CNP, and MAPK3) were elevated and TNF, FGFR2, and IL1B were suppressed by FD.

DoN, GoN and SyT enlisted 8%, 79% and 88% elevated genes, respectively. In DoN, the proteins associated with these transcripts are almost equally distributed among the extracellular space (8 genes), plasma membrane (7 genes), cytoplasm (6 genes) and nucleus (8 genes). On the other hand, proteins encoded by 48% and 71% of the transcripts associated with GoN and SyT, respectively, are localized in the plasma membrane.

FD-elevated transcripts encoding proteins are associated with a wide ensemble of transmembrane receptors and transportation functions (SOX10, CHRNK3, GFR2, NGFR, APBA1, GJBI, SLC1A3, SLC3A7, SLC6A4 and SLC6A5) and membrane-based G-protein coupled receptor (ADRB2, CCR5, CHRM5, CNR1, DRD3, GPR6, GRM2, GRM7, HCRTR1 and NTSR1). FD further increased the expression of most of the genes regulating Impact of Fish Oil on Brain Genomic Profile.
Table 3. Significant biofunctions (p<0.0001) enriched by more than 50 candidates from the 1,142 genes of interest (GOI).

| Biofunction Categories                          | p-values               | Number of Molecules |
|------------------------------------------------|------------------------|---------------------|
| Genetic Disorder                               | 1.09E-3 to 4.24E-6     | 432                 |
| Neurological Disease                           | 1.01E-3 to 5.69E-5     | 260                 |
| Movement disorder                              | 8.13E-04               | 93                  |
| Neuropathy                                      | 2.43E-03               | 88                  |
| Motor neuron disease                           | 1.58E-03               | 86                  |
| Progressive motor neuropathy                   | 1.98E-03               | 85                  |
| Encephalopathy                                 | 1.79E-03               | 85                  |
| Neurodegenerative disorder                     | 4.50E-04               | 76                  |
| Alzheimer's disease                            | 1.11E-03               | 70                  |
| Parkinson's disease                            | 1.26E-03               | 50                  |
| Spinal cord disorder                           | 1.89E-04               | 30                  |
| Gastrointestinal Disease                       | 1.61E-3 to 1.37E-4     | 232                 |
| Metabolic Disease                              | 1.73E-3 to 2.27E-6     | 211                 |
| Tissue Development                             | 1.04E-3 to 1.79E-7     | 202                 |
| Immunological Disease                          | 1.07E-3 to 9.63E-5     | 193                 |
| Cellular Growth and Proliferation              | 1.61E-3 to 5.90E-5     | 184                 |
| Cardiovascular Disease                         | 1.03E-3 to 8.17E-6     | 180                 |
| Endocrine System Disorders                     | 1.73E-3 to 4.57E-5     | 180                 |
| Cellular Development                           | 1.06E-3 to 3.03E-7     | 179                 |
| Cell-To-Cell Signaling and Interaction         | 1.04E-3 to 1.46E-11    | 176                 |
| Molecular Transport                             | 1.01E-3 to 3.48E-6     | 169                 |
| Hematological Disease                          | 1.03E-3 to 1.18E-5     | 165                 |
| Nervous System Development and Function         | 1.04E-3 to 7.83E-7     | 150                 |
| Neurogenesis                                    | 5.91E-06               | 73                  |
| Neurological process of cells                  | 1.01E-07               | 51                  |
| Neurological process of neurons                | 7.83E-07               | 42                  |
| Neurotransmission                              | 2.41E-07               | 37                  |
| Synaptic transmission                          | 4.98E-07               | 35                  |
| Development of brain                           | 2.42E-04               | 33                  |
| Neurotransmission of nervous tissue            | 2.54E-06               | 30                  |
| Organismal Development                         | 1.73E-3 to 2.23E-5     | 149                 |
| Cellular Movement                              | 1.61E-3 to 7.36E-4     | 123                 |
| Embryonic Development                          | 1.54E-3 to 2.23E-5     | 118                 |
| Hematological System Development and Function   | 1.04E-3 to 6.18E-6     | 112                 |
| Inflammatory Disease                           | 1.60E-3 to 2.06E-5     | 111                 |
| Tissue Morphology                              | 1.44E-3 to 3.96E-5     | 109                 |
| Inflammatory Response                          | 3.03E-3 to 6.18E-6     | 108                 |
| Immune response                                | 1.14E-04               | 102                 |
| Activation of leukocytes                        | 7.25E-05               | 50                  |
| Activation of mononuclear leukocytes            | 4.61E-05               | 39                  |
| Activation of lymphocytes                      | 1.49E-04               | 36                  |
| Activation of T lymphocytes                    | 7.59E-05               | 30                  |
| Small Molecule Biochemistry                    | 1.10E-3 to 2.10E-4     | 107                 |
| Organ Development                              | 2.19E-3 to 2.23E-5     | 101                 |
| Dermatological Diseases and Conditions         | 1.73E-3 to 9.63E-5     | 98                  |
| Cell Signaling                                 | 1.01E-3 to 3.48E-6     | 97                  |
| Cell Death                                     | 1.25E-3 to 1.79E-7     | 89                  |
| Apoptosis                                      | 3.03E03 to 8.95E-4     | 43                  |
| Killing                                        | 7.62E-4 to 3.03E-7     | 23                  |
transcription, such as ASCL1, EOM1, HEYL, LDB1, LzTS1, NFATC2, NKX2-2 and RELA, excluding two, EGR2 and LHX2. Alternatively, FD suppressed the transcripts linked to the growth factors (FGF2, HGF and GDF6) and the cytokines (IL1B and TNF). The transcripts regulating the protein kinases displayed a mixed expression profile; ALK, DLG2, KIT, NTRK3 and PRKCD were elevated, but MAPK8 and ROCK1 were suppressed by FD.

3.1.iii. Apoptosis and immune response. Apoptosis and immune response were the two most enriched sub-categories of “cell death” and “inflammatory response” respectively, which explained 48% and 95% of the transcripts enlisted by the respective parent terms. Together, they shared 34 genes; 23 of these were suppressed (Table S5). Most of the proteins encoded by these transcripts associated with apoptosis (30%) and immune response (35%) are localized in the plasma membrane.

The pool of cytokine associated transcripts (CSP2, CXCL11, IK, IL10, IL19, IL1B, PRL, TNF and TNFSF14) was suppressed in FD-fed mice excluding IL23elevated. Likewise, a large panel of CD markers excluding CD4 was suppressed by FD. The list included CD2, CD3G, CD80, CD28 and CD7, which are associated with T-cells; CD5 and CD48 are associated with B-cells; CD244 is associated with both NK-cells and T-cells; and CD226 is associated with platelets as well as T-cells. Alternatively, all the transcripts associated with transportation (GJA4, LBP and SFTPA1) were elevated. Among the growth factors, BMP6 and PFG transcripts were elevated; whereas FGF2 and HGF were suppressed. All of the kinase-transcripts encoding protein localized in the plasma membrane were elevated (ALK, KIT and NTRK3), while the rest (CHEK1, MAPK3, PDK1, PRKX and ROCK1) were suppressed by FD.

3.2 Validation of gene expression by the real-time PCR analysis

The elevated expressions of DRD3, GABBR1, CCKBR and GABRA3 encoding proteins localized in the membrane were validated by PCR array (Figure 4). The suppressed genes validated by qPCR included MAOA, GAD1, HPRT1, NPY1R, CHRNA1, CHRNA3, GABRD and GABRG2. The assay could not confirm the expressions of CHRN2, CHRNA, GABRP and GABRB2.

By using the low throughput qPCR assay (Figure 5), we confirmed that FKBP5 and NOS-1 were elevated by FD while BDNF, MMP9 and SOD1 were suppressed.

Altogether, the qPCR assay validated 76% of the genomic expressions tested herein.

Discussion

A multitude of in vitro results suggest potential benefits of n-3 PUFA enriched diets typically supplemented by fish oil, but translating the knowledge to a viable therapeutic model remains challenging [10,12,15,52–54]. There is a necessity for a more systematic comprehension of the etiologic relationships between the fish oil and their reported effects on various illnesses.

In light of the several studies evaluating the range of the compositions of n-3/n-6 PUFA [21–25,55,56], our study focused on investigating one particular dietary supplement, namely the fish oil enriched with high n-3 PUFAs, EPA and DHA in particular. This high fat composition with a consequence of increased body mass is certainly a concern [57] that should be addressed by a more comprehensive investigation in the future. Furthermore, we investigated the effects on the hemibrains only; dietary effects on various brain sub-regions were not assessed as reported by others [40]. Present study also did not attempt to quantify the shift of fatty acid levels in the brain as a result of consuming a high fat diet that investigated in past [58]. The genomic profiling of the hemibrains could be further biased by the collection of the small midline structures such as thalamic and hypothalamic nuclei.

It is important to note that the present study solicited the molecular impacts of the fish oil, not the consequences of n-3 PUFA. The study was designed to critically comprehend the performances of the fish oil including its benefits and adverse effects. Therefore FD delivered more fish oil derived fatty acids (high n-3 PUFA; but sub-optimal n-6 PUFA) than the controls following many such precedents [42,59–63]. SD with nearly equivalent caloric contribution had unadjusted fat supplements presenting a ratio of 8:1 of n-3 PUFA: n-6 PUFA; the SD contained 0.2% and 1.22% of n-3 and n-6 PUFA, respectively, with a ratio of 1:6. By mass, FD consisted of 16% fish oil, and the total fat composition in FD was 1.5 fold higher than SD. FD
Impact of Fish Oil on Brain Genomic Profile

4.1. Fish oil mediated augmentation of the brain and nervous system

The functional consequences of synaptic plasticity include the power of retention and retrieval of memory; and shifting of learning and behavioral paradigms [66,67]. Environments combined with diets can critically modify the synaptic networks that involve formations, differentiation, repositioning, and elimination of synapse.

The NMDA receptors (NMDARs) are the critical regulators of synaptic plasticity and particularly of the long term consequences such as memory retention [43,66,68,69]. Src-mediated direct phosphorylation of NMDARs initiates the presynaptic influx of Ca\(^{2+}\) [68]. FD apparently activated this presynaptic pathway by elevating the key transcriptional members, including sHIC (also known as SHC3), NMDAR2A (also known as GRIN2A) and CACNA1A. Promoting the excitatory against the inhibitory synaptic transmissions [70], CACNA1A contributes to a number of neurological disorders [71]. Unlike CACNA1A, which closely regulates the nervous system, CACNA1S suppressed by FD is associated with photoreception and thermoregulation [72,73].

NMDAR-mediated influx of Ca\(^{2+}\) contributes to the long term potentiation, thereby controlling the behavioral learning, fear response and extinction [66,69,74]. Related observation of elevated nGluR2 (GRM2) in FD-fed mice was rather counterintuitive. nGluR2 in association with moderate Ca\(^{2+}\) influx is linked to long term depression [73]. Addressing the paradox, literatures suggest that the temporal pattern of Ca\(^{2+}\) deposits may shift the consequence from depression to potentiation, and differential buffering of intracellular Ca\(^{2+}\) may also shift the balance [68]. Although we could not rule out the possibility of FD-induced long term depression, our results described hereafter increasingly favored the possibility that FD preferentially promoted long term potentiation.

Supporting the hypothesis, FD enhanced glutamatergic activity (elevated DRD-2/-3/-5, GRM-2/-7, and GRI-D2/-N2a in the FD-fed mice) driving the calcium and dopamine messengers to phosphorylate the protein phosphatase 1 regulatory subunit 1B [69]. Elevated PPP1R1B, also observed by administering DHA-enriched diet [40] is critically related to the emotional learning associated with long term potentiation [76]. In addition, FD elevated a group of transcriptional members associated with choline influx, such as CHRM3, CHRNA3 and SLC5A, which typically promote long term potentiation [77]. FD induced elevation of PDPK1 and AKT (alternate name: PKB), two integral downstream members of PI3K pathways, is likely to cause spine

Figure 2. Regulatory networks showing the clusters of differentially regulated genes involved in “neurological diseases”. The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log\(_{10}\) \(p\)-values of 1.11 \(10^{-6}\) and 1.26 \(10^{-6}\), respectively. doi:10.1371/journal.pone.0090425.g002

4.1. Fish oil mediated augmentation of the brain and nervous system

The functional consequences of synaptic plasticity include the power of retention and retrieval of memory; and shifting of learning and behavioral paradigms [66,67]. Environments combined with diets can critically modify the synaptic networks that involve formations, differentiation, repositioning, and elimination of synapse.

The NMDA receptors (NMDARs) are the critical regulators of synaptic plasticity and particularly of the long term consequences such as memory retention [43,66,68,69]. Src-mediated direct phosphorylation of NMDARs initiates the presynaptic influx of Ca\(^{2+}\) [68]. FD apparently activated this presynaptic pathway by elevating the key transcriptional members, including sHIC (also known as SHC3), NMDAR2A (also known as GRIN2A) and CACNA1A. Promoting the excitatory against the inhibitory synaptic transmissions [70], CACNA1A contributes to a number of neurological disorders [71]. Unlike CACNA1A, which closely regulates the nervous system, CACNA1S suppressed by FD is associated with photoreception and thermoregulation [72,73].

NMDAR-mediated influx of Ca\(^{2+}\) contributes to the long term potentiation, thereby controlling the behavioral learning, fear response and extinction [66,69,74]. Related observation of elevated nGluR2 (GRM2) in FD-fed mice was rather counterintuitive. nGluR2 in association with moderate Ca\(^{2+}\) influx is linked to long term depression [73]. Addressing the paradox, literatures suggest that the temporal pattern of Ca\(^{2+}\) deposits may shift the consequence from depression to potentiation, and differential buffering of intracellular Ca\(^{2+}\) may also shift the balance [68]. Although we could not rule out the possibility of FD-induced long term depression, our results described hereafter increasingly favored the possibility that FD preferentially promoted long term potentiation.

Supporting the hypothesis, FD enhanced glutamatergic activity (elevated DRD-2/-3/-5, GRM-2/-7, and GRI-D2/-N2a in the FD-fed mice) driving the calcium and dopamine messengers to phosphorylate the protein phosphatase 1 regulatory subunit 1B [69]. Elevated PPP1R1B, also observed by administering DHA-enriched diet [40] is critically related to the emotional learning associated with long term potentiation [76]. In addition, FD elevated a group of transcriptional members associated with choline influx, such as CHRM3, CHRNA3 and SLC5A, which typically promote long term potentiation [77]. FD induced elevation of PDPK1 and AKT (alternate name: PKB), two integral downstream members of PI3K pathways, is likely to cause spine
## Table 4.
The genomic candidates associated with three top-ranked neurological diseases: movement disorder (MvD), Alzheimer’s disease (AD) and Parkinson’s disease (PD).

| Entrez ID | Gene Symbol | Log Ratio | Neurological Disease |
|-----------|-------------|-----------|----------------------|
| 16521     | KCNJ5       | 1.45      | AD                   |
| 20660     | SORL1       | 1.32      | AD, MvD              |
| 14397     | GABRA4      | 1.27      | AD, MvD, PD          |
| 15360     | HMGC52      | 1.24      | MvD                  |
| 20508     | SLC1A8A3    | 1.20      | MvD                  |
| 108068    | GRM2        | 1.18      | AD                   |
| 99738     | KCNC4       | 1.17      | AD, MvD, PD          |
| 18053     | NGFR        | 1.15      | AD                   |
| 76829     | DOK5        | 1.13      | AD                   |
| 214779    | ZNF479      | 1.12      | MvD, PD              |
| 12671     | CHRM3       | 1.11      | AD, MvD, PD          |
| 108043    | CHRN83      | 1.11      | AD, MvD, PD          |
| 12661     | CHL1        | 1.10      | AD                   |
| 108073    | GRM7        | 1.05      | AD, MvD, PD          |
| 94187     | ZNF423      | 1.05      | MvD                  |
| 20618     | SNCG        | 1.03      | MvD, PD              |
| 68957     | PAQR6       | 1.02      | MvD, PD              |
| 17441     | MOG         | 1.01      | MvD, PD              |
| 140741    | GPR6        | 1.01      | MvD                  |
| 110893    | SLC8A3      | 0.98      | MvD, PD              |
| 14811     | GRIN2A      | 0.98      | AD, MvD, PD          |
| 16504     | KCNC3       | 0.97      | MvD                  |
| 16772     | LAMA1       | 0.96      | AD                   |
| 114142    | FOXP2       | 0.96      | MvD, PD              |
| 72605     | CA10        | 0.94      | AD                   |
| 224129    | ADCV5       | 0.92      | MvD                  |
| 12801     | CNR1        | 0.88      | AD, MvD, PD          |
| 26380     | ESR8B       | 0.86      | AD                   |
| 71137     | RFX4        | 0.85      | MvD                  |
| 63993     | SLC5A7      | 0.84      | AD                   |
| 213262    | FSTL5       | 0.83      | AD, MvD, PD          |
| 140919    | SLC17A6     | 0.83      | AD, MvD, PD          |
| 18213     | NTRK3       | 0.80      | AD, MvD, PD          |
| 15567     | SLC6A4      | 0.80      | AD, MvD              |
| 16536     | KCNQ2       | 0.78      | MvD                  |
| 19049     | PPP1R1B     | 0.78      | MvD                  |
| 12161     | BMP6        | 0.75      | AD                   |
| 407831    | TMEM204     | 0.74      | MvD, PD              |
| 19281     | PTPRT       | 0.73      | AD, MvD, PD          |
| 20191     | RYR2        | 0.73      | AD                   |
| 21834     | THR8        | 0.71      | MvD, PD              |
| 226922    | KCNQ5       | 0.69      | MvD, PD              |
| 218763    | LRRCD3      | 0.69      | AD                   |
| 192167    | NLGN1       | 0.68      | MvD, PD              |
| 230777    | HCRTR1      | 0.67      | MvD                  |
| 18610     | PDYN        | 0.67      | MvD                  |
| 239133    | DLEU7       | 0.66      | MvD, PD              |
| 12286     | CACNA1A      | 0.66     | MvD                  |

## Table 4. Cont.

| Entrez ID | Gene Symbol | Log Ratio | Neurological Disease |
|-----------|-------------|-----------|----------------------|
| 23859     | DLG2        | 0.64      | MvD, PD              |
| 17172     | ASCL1       | 0.64      | MvD                  |
| 213783    | PLEKHG1     | 0.64      | AD                   |
| 72844     | KCTD17      | 0.62      | MvD                  |
| 70357     | KCNIP1      | 0.62      | MvD                  |
| 20745     | SPOCK1      | 0.60      | AD                   |
| 13492     | DRD5        | 0.59      | AD, MvD, PD          |
| 67703     | KIRREL3     | 0.59      | AD                   |
| 16493     | KCNA5       | 0.59      | MvD                  |
| 14169     | FGF14       | 0.56      | MvD                  |
| 269132    | GLT25D2     | 0.56      | MvD, PD              |
| 11550     | ADRA1D      | 0.54      | AD, MvD, PD          |
| 18125     | NOS1        | 0.54      | AD, MvD, PD          |
| 21955     | TNNT1       | 0.53      | MvD                  |
| 12950     | HAPLN1      | 0.53      | AD                   |
| 12289     | CACNA1D     | 0.52      | AD, MvD, PD          |
| 16785     | RPSA        | 0.52      | MvD                  |
| 319924    | APBA1       | 0.51      | AD                   |
| 269513    | NKAIN3      | 0.50      | AD, MvD, PD          |
| 16409     | ITGAM       | 0.49      | MvD                  |
| 94253     | HECW1       | 0.49      | AD                   |
| 12265     | CIITA       | 0.49      | AD                   |
| 11555     | ADRA2B      | 0.47      | AD, MvD              |
| 14407     | GABRG3      | 0.46      | AD, MvD, PD          |
| 14407     | GABRG3      | 0.46      | MvD                  |
| 58178     | SORCS1      | 0.45      | AD                   |
| 12411     | CBS         | 0.44      | AD                   |
| 12336     | CAPNS1      | 0.44      | MvD                  |
| 12048     | BCL2L1      | 0.44      | MvD                  |
| 435965    | LRP3        | 0.44      | AD                   |
| 16597     | KLF12       | 0.43      | MvD, PD              |
| 170735    | ARR3        | 0.43      | MvD                  |
| 14708     | GNCG        | 0.43      | MvD, PD              |
| 241494    | ZNF385B     | 0.43      | MvD, PD              |
| 16522     | KCNJ6       | 0.41      | MvD, PD              |
| 29856     | SMTN        | 0.40      | MvD                  |
| 231872    | AIMP2       | 0.39      | MvD                  |
| 56807     | SCAMP5      | 0.39      | MvD                  |
| 54218     | B3GALTL4    | 0.37      | MvD                  |
| 14680     | GNAL        | 0.36      | MvD                  |
| 20249     | SCD         | 0.35      | AD, MvD              |
| 13033     | CSA         | 0.35      | AD                   |
| 19697     | RELA        | 0.34      | AD, MvD, PD          |
| 14804     | GRID2       | 0.32      | AD, MvD              |
| 18753     | PRKCD       | 0.31      | AD                   |
| 12799     | CNP         | 0.30      | AD, MvD, PD          |
| 17528     | MPZ         | 0.29      | MvD                  |
| 18019     | NFATC2      | 0.27      | AD                   |
| 244431    | SGCZ        | 0.25      | MvD, PD              |
enlargement and stability, thus promoting long term potentiation maintenance [78].

Together, the accumulated evidence from this study increasingly linked FD to long term potentiation, as opposed to long term depression.

Emerging knowledge elucidating the complexity of BDNF activity regulation begins to dissociate BDNF from the robust synapse as suggested in past [79–81]. Researchers have found that the TRKB-independent pro-BDNF signaling pathway is the causative factor of compromised synapse [82], and potentially eliciting depression [83]. In comparison to the remote PTSD patients, recent PTSD patients have been diagnosed with higher levels of BDNF that likely contribute to the biased consolidation of fear memory [84]. Evidently, the memory consolidation process is exon-specific. Prolonged stress applied on the rodents significantly elevated BDNF mRNA levels in exon I (35%), IV (20%) and IX (16%), and substantially elevated mRNA of exon II (20%) [85]. In this context, our microarray data predicted suppressed exon II of BDNF (NM_007540, vendor-delivered information, Table S1) in FD-fed mice, and the qPCR assay (Figure 5) validated the outcome.

Conversion of pro-BDNF to mature BDNF is mediated by MMP-9, [86,87], which was transcriptionally suppressed by FD. Supporting evidence reported the n-3 PUFA-induced inhibition of MMP-9 in brain cells challenged by an endotoxic assault in vitro [87].

Hence, we postulate that FD promotes axonal growth by steering a BDNF-independent network critically regulated by Src to activate PI3K-AKT-PKC downstream. In fact, the independent actions of Src and BDNF have been reported in the past as a response to a dietary imbalance caused by zinc deficiency [88].

### 4.2 Fish oil mediated neuroprotection

Consistent with a past study [40], here we also reported a host of elevated genes in FD-fed mice associated with the myelin accumulation and preservation, including MOG, MPZ and MAG. Demyelinated lesions in neuronal cells are early indicators of inflammation that lead to the rapid destruction of the myelin sheath, causing increased vulnerability of the axons [89]. In fact, selective loss of MOG was identified as a serologic marker of inflammatory brain disease [90].

Pro-inflammatory cytokines such as TNF-α, IL-1B, IL-10 and TNFSF1 showed decreased transcriptomic expression, while the transcription of interferon gamma antagonist (Il2) was elevated by FD in accordance to many past studies [91–94]. A study conducted on healthy young human adults identified the lower levels of n-3 PUFA (or a higher n-6: n-3 ratio) in serum as the primary cause of the larger influx of IFN-γ and TNF-α [6,95]. Of particular note, we observed elevated RELA in FD mice; a rather counterintuitive observation, particularly in light of the suppressed expression of related genes like TNF, and the relevant past studies [96]. One possible reason could be the near obesity condition of the FD-fed mice; a high fat diet allegedly increases NF-κB activities in rodents [97].

The immunological implications of fish oil were further supported by the comprehensive FD induced suppression of CD markers associated with T-cells, B-cells, NK-cells and platelets. Emerging knowledge suggests that there are inhibitory effects of n-3 PUFA on CD cells, the potential markers of depression [98].

Down-regulation of apoptotic pathways and promotion of cell survival are known implications of n-3 PUFA enriched diets. Elevated AKT and BCL2/1A in FD-fed mice are the established markers of cell survival [99] [100]. The suppressed genes encoding the caspase family (Casp -1/-4/-7/-14) may suggested the diet’s potential protective roles against inflammation by regulating the caspase family members [101–103].

### 4.3 Potential therapeutic efficacy of FD treating neurodegenerative disorders

The motivation of testing fish oil as the dietary supplements could be derived from the ongoing clinical trial activities evaluating the agonists of GABRG-3, GABRA-4, DRD-5, and THRB (all were elevated by FD), and the antagonists of GABRA-5 (suppressed by FD) for treating depression (www.clinicaltrials.gov). On the other hand, the antagonists targeting GABRG-3, GABRG-4, DRD5, ADR –A1D–B2, CHRM-3, and SLCOA4

| Table 4. Cont. |
|-----------------------------------------------|
| Entrez ID | Gene Symbol | Log Ratio | Neurological Disease |
| 241263 | GPR183 | 0.24 | AD |
| 20655 | SOD1 | –0.32 | AD, MvD, PD |
| 16439 | ITPR2 | –0.33 | AD |
| 110796 | TSHZ1 | –0.34 | AD |
| 26419 | MAPK8 | –0.35 | AD |
| 110886 | GABRA5 | –0.37 | AD, MvD, PD |
| 19108 | PRKX | –0.37 | MvD |
| 239743 | KHL16 | –0.39 | AD |
| 16176 | IL1B | –0.44 | AD, MvD, PD |
| 20102 | RPS54X | –0.45 | MvD, PD |
| 12292 | CACNA15 | –0.47 | AD, MvD, PD |
| 249331 | TSHZ3 | –0.47 | AD |
| 11813 | APOC2 | –0.50 | AD |
| 17536 | MEIS2 | –0.50 | MvD |
| 50790 | ACSL4 | –0.51 | AD |
| 68272 | RBM28 | –0.52 | AD |
| 15279 | E2F7 | –0.55 | MvD, PD |
| 18386 | OPWD1 | –0.60 | MvD |
| 19366 | RAD54L | –0.61 | MvD |
| 23653 | EGR1 | –0.61 | MvD |
| 39625 | GALT | –0.65 | MvD, PD |
| 72519 | TMEM55A | –0.67 | MvD, PD |
| 13654 | EGR2 | –0.69 | MvD |
| 117591 | SLCA9 | –0.71 | AD |
| 435726 | KCNMB3 | –0.79 | MvD, PD |
| 77055 | KRT76 | –0.81 | AD |
| 21785 | TFF2 | –0.85 | MvD, PD |
| 14173 | FGF2 | –0.87 | AD, MvD |
| 12363 | CASP4 | –0.96 | AD |
| 16153 | IL10 | –0.97 | MvD, PD |
| 252973 | GRHL2 | –1.03 | AD |
| 76645 | PKD1L2 | –1.05 | MvD, PD |
| 21926 | TNF | –1.21 | AD, MvD, PD |
| 14686 | GNAT2 | –1.94 | MvD |
| 19109 | PRL | –2.23 | MvD |

The genes are identified by the Entrez ID and gene symbol. The log ratio indicates the log_{1.5} transformed of the average transcriptomic expression from FD-/SD-fed mice.

doi:10.1371/journal.pone.0090425.t004
(all elevated by FD) are under investigation for treating bipolar disorder and schizophrenia.

In contrast, FD-regulated transcripts could be relevant in eliciting the risk of the schizophrenia, bipolar disorder, and suicidal inclination. FD, for instance activated ADR-A1D/-B2 and SLC6A4; and the activated adrenergic and serotonergic pathways are linked to augment the suicidal psychopathology [104]. In addition, several of the GABA family members (GABRG-3, GABRG-4) and key dopamine receptors (DRD5) were also elevated by FD. The activities of GABA families and dopaminergic hyperactivity are positively correlated with the prevalence of bipolar disorder and schizophrenia [105] [106]. Contrastingly, dopaminergic hypoactivity has been recognized as a possible precursor of depression [107]. This observation emphasizes the fact that the efficacy of fish oil potentially depends on the disease pathophysiology.

Affective disorder is typically triggered by the decreased activities of antioxidants such as glutathione and the depletion of serological markers such as BDNF and somatostatin [108]. Our report showed FD-induced elevation of a number of transcripts related to transmembrane glutathione transfer (Gstm -4/6, and Gtt-4) (Table S2) accompanied by CORT encoding cortistatin, and thereby likely activated of the somatostatin receptors. Among other neurodegenerative diseases, the reported impacts of FD on AD and PD were in accordance with a multitude of existing evidence [9,10,12,31]. FD suppressed APBA1, a key gene encoding the amyloid beta (A4) precursor protein-binding family; thereby potentially suppressed the amyloidal toxicity, a vital precursor of AD progression [109]. Possible activation of the dopaminergic cascade, evident from the elevated receptors (DRD-2/3/5-5), indicated a stronger efficacy of FD in treating PD.

In addition, FD altered a collection of transcriptomic expression linked to AD and PD onset [110,111], such as NOS-2, SOD1 and caspases (CASP-1/-4/-7). Accumulated evidences underscore the importance of the beta-adrenergic receptors and MAPK signaling towards AD pathology [112]; members of these respective networks (ADR-A1D/-B2 and MAPK-8) were altered by FD.

FD mice showed a comprehensive elevation of the transcripts associated with voltage-gated potassium channels (KCNMB3, KCNQ5, KCNN1P1, KCNCA, KCNAC, KCNMA5, KCNQ6, KCTD7 and KCNQ2) and cholinergic modulation (CHRM3 and CHRNA3), which are associated with memory consolidation and stress management [113–115]. Among another psychological illnesses, FD showed positive implications in PTSD, regulating some of the potential therapeutic markers like BDNF, FKBP5 and SLC6A4 [116] (Table 2). In addition, Table 2 shows a list of psychological deilities associated with a panel of transcripts investigated by qPCR.

Conclusions

The biomechanisms exhibited by the fish oil that facilitate neurotrophic regulation are still elusive. The knowledge gap limits our predictive aptitude in realistically estimating the efficacy of this dietary supplement. To address this challenge, we customized a diet enriched of 16% fish oil by weight, the optimum fraction of oil added to the rodent food without altering its texture from the standard lab diet. Two randomly chosen groups of C57BL/6j mice consumed one of the two diets from weaning age until their young adulthood. We sacrificed five month old mice and investigated their hemibrains using a genome-wide transcriptomic platform.

Functional analyses of the transcriptomic data focused on the areas of the neurogenesis, neuroviability and neurodegenerative disorders. The GOI were clustered into four most significant functions: “Neurological disease”, “Nervous system development and function”, “Immune response” and “Apoptosis”. Together these functions encompassed 247 transcripts (~20%) identified from

---

**Figure 3. Regulatory networks showing the clusters of differentially-regulated genes involved in “nervous development and functions”.** The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log2(FD-/SD-fed mice) in the FD-fed mice compared to the SD-fed mice (a color scale is at the bottom right corner). The genes are clustered based on their proteins’ cellular locations in the nucleus, cytoplasm, plasma membrane, and extracellular space. The genes without the location information are grouped under ‘unknown’.
Table 5. The genomic candidates associated with two top-ranked “nervous system development and functions”: neurogenesis (Ngs) and the synaptic transmission (SyT).

| Entrez ID | Gene symbol | Log Ratio | Nervous system development and functions |
|-----------|-------------|-----------|------------------------------------------|
| 11922     | NEUROD6     | 2.22      | Ngs (Ntg, FPMP, DCNS, DoN)               |
| 18530     | PCDH8       | 2.12      | SyT                                      |
| 211134    | LZTS1       | 1.80      | Ngs (Ntg, FPMP, DCNS)                    |
| 319922    | VWC2        | 1.43      | Ngs (DCNS, DoN)                          |
| 56198     | HEYL        | 1.35      | Ngs (DoN)                                |
| 21960     | TNR         | 1.24      | SyT                                      |
| 20508     | SLC18A3     | 1.20      | Ngs (Ntg, FPMP)                          |
| 108068    | GRM2        | 1.18      | SyT                                      |
| 14618     | JGB1        | 1.15      | Ngs (GoN, DCNS)                          |
| 18053     | NGFR        | 1.15      | Ngs (Ntg, FPMP, GoN, DCNS, DoN)          |
| 76829     | DOK5        | 1.13      | Ngs (GoN)                                |
| 12671     | CHRM3       | 1.11      | SyT                                      |
| 108043    | CHRNB3      | 1.10      | SyT                                      |
| 12661     | CHL1        | 1.10      | Ngs (Ntg, FPMP, DCNS, DoN)               |
| 18216     | NTSR1       | 1.07      | SyT                                      |
| 108073    | GRM7        | 1.05      | SyT                                      |
| 20618     | SNCG        | 1.03      | SyT                                      |
| 65254     | DPYS5L5     | 1.02      | Ngs (GoN)                                |
| 140741    | GPR6        | 1.01      | Ngs (GoN)                                |
| 12774     | CCR5        | 0.99      | Ngs (DoN)                                |
| 110893    | SLC8A3      | 0.98      | SyT                                      |
| 14811     | GRIN2A      | 0.98      | SyT                                      |
| 16772     | LAMA1       | 0.96      | Ngs (Ntg, GoN, FPMP)                     |
| 18088     | NKX2-2      | 0.93      | Ngs (DCNS, DoN)                          |
| 17136     | MAG         | 0.90      | Ngs (Ntg, GoN, FPMP)                     |
| 12801     | CNR1        | 0.88      | SyT, Ngs (GoN, DCNS, DoN)                |
| 53404     | ATOH7       | 0.85      | Ngs (GoN, DoN)                           |
| 63993     | SLC5A7      | 0.84      | SyT                                      |
| 20418     | SHC3        | 0.80      | SyT, Ngs (DCNS, DoN)                     |
| 18213     | NTRK3       | 0.80      | Ngs (Ntg, GoN, FPMP, DoN)                |
| 15567     | SLC6A4      | 0.80      | Ngs (DCNS, DoN)                          |
| 20665     | SOX10       | 0.80      | Ngs (DCNS)                               |
| 19049     | PPP1R1B     | 0.78      | Ngs (DoN)                                |
| 12570     | CDK5R2      | 0.77      | Ngs (GoN, DCNS, DoN)                     |
| 12161     | BMP6        | 0.75      | Ngs (GoN, DoN)                           |
| 20562     | SLIT1       | 0.74      | Ngs (Ntg, GoN, FPMP, DCNS)               |
| 21834     | THR8        | 0.71      | Ngs (DCNS)                               |
| 22422     | WNT7B       | 0.70      | Ngs (Ntg, FPMP)                          |
| 192167    | NLGN1       | 0.68      | SyT, Ngs (DoN)                           |
| 230777    | HCRTR1      | 0.67      | SyT                                      |
| 16590     | KIT         | 0.66      | Ngs (GoN)                                |
| 12286     | CACNA1A     | 0.66      | Ngs (Ntg, FPMP, DCNS, DoN)               |
| 18081     | NINJ1       | 0.66      | Ngs (GoN)                                |
| 22421     | WNT7A       | 0.65      | Ngs (Ntg, FPMP, DoN)                     |
| 23859     | DLG2        | 0.64      | SyT                                      |
| 17172     | ASCL1       | 0.64      | Ngs (Ntg, FPMP, DCNS, DoN)               |
| 13616     | EDN3        | 0.63      | Ngs (DoN)                                |
| 12005     | AXIN1       | 0.62      | Ngs (FPMP)                               |
1,142 genes displaying the most differential expression between the FD- and SD-fed mice. Approximately 40% of the proteins associated with these genes are located in the plasma membrane, suggesting a biased impact of the fish oil on the membrane-associated activities. Leveraging from the mouse brain atlas (mouse.brain-map.org) we found several of these genes found enriching the brain regions (Table S4) such as olfactory bulb, cerebellar cortex, thalamus and amygdala typically associated with the motor activities, information relay and neuropsychology.

In FD-fed mice, a Src-mediated calcium-controlled network was suggested to reinforce synapse that possibly operated in a BDNF-MMP-9 independent pathway. FD suppressed the transcription of BDNF exons II, which is known to express in response to stress [85]. Activated PI3K-AKT-PKC cascades operated in concert. We further acknowledged a risk of spurring depression through FD-mediated activation of mGluR2/Ca$^{2+}$ [75]. However, the FD-induced long term potentiation was deemed as more plausible endpoint in cognition of the additional evidences, including the stimulation of NMDAR and downstream glutaminergic/dopaminergic/cholinergic networks [69,77] and the elevated transcription of WNT family genes [117], PPP1R1B [76] and NEUROD6 [118]. The risk of Ca$^{2+}$-induced biased recurrence of excitatory synaptic transmission was possibly mitigated by the FD-induced NLGN1 that typically helps in restoring the balance between the excitatory and inhibitory synapses [119].

FD-induced attenuation of oxidative stress and reduction of amyloidal burden coupled with suppressed inflammatory and apoptosis networks affirmed the potential efficacy of fish oil in

| Entrez ID | Gene symbol | Log Ratio | Nervous system development and functions |
|-----------|-------------|-----------|----------------------------------------|
| 70357     | KCNIP1      | 0.62      | SyT                                    |
| 13492     | DRD5        | 0.59      | SyT                                    |
| 13796     | EMX1        | 0.56      | Ngs (DCNS, DoN)                        |
| 11682     | ALK         | 0.54      | Ngs (GoN)                              |
| 18125     | NOS1        | 0.54      | Ngs (Ntg, FPMP, DoN)                   |
| 319924    | APBA1       | 0.51      | SyT                                    |
| 22412     | WNT9B       | 0.48      | Ngs (DoN)                              |
| 11555     | ADRB2       | 0.47      | SyT, Ngs (GoN, DCNS)                   |
| 22248     | UNC119      | 0.46      | SyT                                    |
| 12048     | BCL2L1      | 0.44      | Ngs (DCNS, DoN)                        |
| 14586     | GFRA2       | 0.39      | Ngs (Ntg, GoN, FPMP)                   |
| 67903     | GIPC1       | 0.37      | SyT                                    |
| 16825     | LDB1        | 0.37      | Ngs (DCNS)                            |
| 19697     | RELA        | 0.34      | Ngs (GoN)                            |
| 14804     | GRID2       | 0.32      | SyT                                    |
| 18753     | PRKCD       | 0.31      | Ngs (GoN)                            |
| 12799     | CNP         | 0.30      | SyT, Ngs (Ntg, FPMP)                   |
| 17528     | MPZ         | 0.29      | SyT, Ngs (Ntg, GoN, FPMP)              |
| 13871     | ERCC2       | 0.28      | Ngs (DCNS, DoN)                        |
| 18019     | NFATC2      | 0.27      | Ngs (GoN)                            |
| 171166    | MCOLN3      | 0.22      | Ngs (DoN)                            |
| 241568    | LRRCA4C     | 0.26      | Ngs (Ntg, FPMP)                        |
| 242316    | GDF6        | 0.28      | Ngs (FPMP, DoN)                       |
| 18126     | NOS2        | 0.32      | Ngs (DCNS)                            |
| 26419     | MAPK8       | 0.35      | Ngs (Ntg, FPMP, GoN, DCNS, DoN)        |
| 110886    | GABRA5      | 0.37      | SyT                                    |
| 15234     | HGF         | 0.38      | Ngs (Ntg, FPMP, GoN, DCNS, DoN)        |
| 18870     | LHX2        | 0.39      | Ngs (DCNS, DoN)                       |
| 16176     | IL1B        | 0.44      | SyT, Ngs (Ntg, FPMP, GoN, DCNS, DoN)   |
| 19877     | ROCK1       | 0.61      | Ngs (GoN, FPMP)                       |
| 13654     | EGR2        | 0.69      | Ngs (DCNS)                            |
| 216858    | KCTD11      | 0.73      | Ngs (DoN)                            |
| 14173     | FGF2        | 0.87      | SyT, Ngs (Ntg, FPMP, GoN, DCNS, DoN)   |
| 21926     | TNF         | 1.21      | SyT, Ngs (Ntg, GoN, FPMP, DCNS)        |

The neurogenesis biofunction is subsequently subcategorized into differentiation of neurons (DoN), growth of neurites (GoN), differentiation of nervous system (DNS), formation of plasma membrane projections (FPMP), and neuritogenesis (Ntg). The genes are identified by the Entrez IDs and gene symbols. The log ratio indicates the log$_{1.5}$ transformed of the average transcriptomic expressions from FD-/SD-fed mice.

doi: 10.1371/journal.pone.0090425.t005
treating a range of neurodegenerative debilities such as affective, Alzheimer’s and Parkinson’s disorders. In contrast, the FD-stimulated neuromodulators like dopamine, choline, GABA and glutamate may diminish the efficacy of the fish oil in treating bipolar disorder, schizophrenia and suicidal inclination, which has been proposed to be triggered by the hyperactivity of the same pool of molecular messengers [105,106]. Taken together, our results suggested a potential susceptibility of the fish oil’s efficacy on the disease pathology and highlighted the need for strategic repositioning of the fish oil as a therapeutic adjuvant. Supporting our results a number of past in vitro rodent models [41] [37] [35,36,38,39] reported n-3 PUFA benefits in the restoration of myelin sheath, activation of dopaminergic networks with downstream elevation of PPP1R1B, activation of synaptic plasticity and comprehensive attenuation of inflammasome networks.

In conclusion, fish oil could provide therapeutic benefits for a number of neurodegenerative diseases, while there is a valid concern about its therapeutic efficacy in treating certain other illnesses. The comprehensive investigation to confirm these findings are exigent and the effectiveness of this fish oil diet...
should be validated by introducing this diet type to specific disease models.

Supporting Information

Figure S1 The volcano plot of the GOI depicting the expression distribution in FD and SD fed murine hemibrains. Here the x-axis depicts the log2(fold change) and y-axis depicts -log10(p-value), where p-value is calculated by FDR algorithm. The red and green dots represent the up- and down-regulated transcripts, respectively. (TIF)

Figure S2 Regulatory networks showing an additional three clusters of differentially-regulated genes involved in “neurogenesis”. The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log1.5 (FD-/SD-fed mice) in the FD-fed mice compared to the SD-fed mice (a color scale is at the bottom right corner). The genes are clustered based on their proteins’ cellular locations in the nucleus, cytoplasm, plasma membrane, and extracellular space. Three subgroups are “differentiation of nervous system” (left panel), “formation of plasma membrane and extracellular space” (middle panel) and “neurogenesis” (right panel). They enlist 29, 26, and 23 genes with p values of 7.6×10⁻²³, 4.71×10⁻¹⁹ and 8.02×10⁻¹⁸, respectively. (TIF)

Table S1 List of primers and probes used in qPCR assay. (DOCX)

Table S2 List of 1,142 genes of interest (GOI). The genes are identified by the Gene Name and gene symbol. The log ratio indicates the log1.5 transformed of the average transcriptomic expressions from FD-/SD-fed mice. (DOCX)

Table S3 Complete list of biofunction categories enriched by 1,142 genes. For individual functional categories, corresponding range of p values and the number of enriching genomic members are reported. (DOCX)

Table S4 The brain regions enriched by the genes mined by present study relevant to “Neurological disease”, “Nervous system development and function”, “Inflammatory response” and “Cell death”. (DOCX)

Table S5 The genomic candidates associated with apoptosis (Apop) and immune response (ImRes). The genes are identified by the Entrez IDs and gene symbols. The log ratio indicates the log1.5 transformed of the average transcriptomic expressions from FD-/SD-fed mice. (DOCX)

Acknowledgments

We thank Dr. Joseph Palmer, Dr. Fraser Glenn, Ms. Linda Brennan, Mr. William Santos, Dr. Julia Scheerer and three anonymous reviewers for their helpful inputs. Disclaimers: The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as official Department of the Army position, policy, or decision, unless so designated by other official documentation. Research was conducted in compliance with the Animal Welfare Act, and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals (NRC 2011) in facilities that are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International. Citations of commercial organizations or trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

Author Contributions

Conceived and designed the experiments: RH NC MJ. Performed the experiments: AG SM SAM JM. Analyzed the data: NC RH SM. Contributed reagents/materials/analysis tools: AG NC SM. Wrote the paper: NC RH.

References

1. Deckelbaum RJ, Torrejon C (2012) The omega-3 fatty acid nutritional landscape: health benefits and sources. J Nutr 142: 5878–5918.
2. See T, Blumer WS, Deckelbaum RJ (2005) Omega-3 fatty acids: molecular approaches to optimal biological outcomes. Curr Opin Lipidol 16: 11–18.
3. Amminger GP, Schaffer MR, Papageorgiou K, Klier CM, Cotton SM, et al. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67: 146–154.
4. Kicior-Glaser JK, Behary MA, Andridge R, Malarkey WB, Hwang BS, et al. (2012) Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 26: 490–495.
5. Im DS (2012) Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 51: 232–237.
6. Kicior-Glaser JK, Behary MA, Andridge R, Malarkey WB, Glaser R (2011) Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun 25: 1725–1734.
7. Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, et al. (2011) Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study. Arch Ophthalmol 129: 758–766.
8. Tso J, Ross RJ, Herzlich AA, Shen D, Ding X, et al. (2009) A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol 175: 799–807.
9. Hoornmans CR, Pasker-de Jong PC, de Vries RB, Riskes-Hoitinga M (2012) The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer’s pathology in animal models of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 20: 191–209.
10. Jicha GA, Markesbery WR (2010) Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clin Interv Aging 5: 45–61.
11. Bouquet M, Calon F, Cicchetti F (2011) Impact of omega-3 fatty acids in Parkinson’s disease. Ageing Res Rev 10: 453–463.
12. da Silva TM, Munhoz RP, Almeida C, Nalivaiko K, Kius A, et al. (2008) Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111: 351–359.
13. Lesperance F, Fureaux-Smith N, StAndre E, Turecki G, Lesperance P, et al. (2011) The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 72: 1054–1062.
14. Logan AG (2004) Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis 3: 25.
15. Ross BM (2009) Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins Leukot Essent Fatty Acids 81: 309–312.
16. Brenna JT, Duyz Y (2007) The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 77: 247–250.
17. Cole GM, Ma OI, Fratuchy SA (2009) Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 81: 213–221.
18. Duffy EM, Menagh GK, McMillan SA, Strain JJ, Hannigan BM, et al. (2004) The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 31: 1551–1556.
19. Matsuska Y (2011) Clearance of fear memory from the hippocampus through neurogenesis by omega-3 fatty acids: a novel preventive strategy for posttraumatic stress disorder? Biopsychosoc Med 5: 3.
20. Ross BM, Seguin J, Stiewerle LE (2007) Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 6: 21.
21. Mattson MG, (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28: 325–342.
47. Hammamieh R, Chakraborty N, Miller SA, Waddy E, Barmada M, et al.
46. Hammamieh R, Chakraborty N, De Lima TC, Meyerhoff J, Gautam A, et al.
45. Cunnane SC, Keeling PW, Thompson RP, Crawford MA (1984) Linoleic acid
44. Bourre JM, Piciotti M, Dumont O, Pascal G, Durand G (1990) Dietary linoleic
43. Balcombe JP, Barnard ND, Lusardi C, Lusardi M, Arai H, et al. (2007) Differential effects of omega-3 and omega-6 Fatty acids on gene expression in breast cancer cells. Breast Cancer Res Treat 101: 7–16.
42. Freeman MP, Bibbien JR, Winner KL, Brumback BH, Waterman M, et al. (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113: 31–33.
41. Atrash PB, Lawson S, Samogorski A, Sinclair AJ (1996) Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 Suppl: S157–161.
40. Conklin SM, Manuck SB, Yao JK, Flory JD, Bibbien JR, et al. (2007) High omega-6 and low omega-3 fatty acids are associated with depressive symptoms in hospitalized psychiatric in-patients. Psychol Med 39: 932–942.
39. Begg DP, Galon F, Morihara T, Yang F, Teter B, et al. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25: 3032–3040.
38. Hennebel M, Belleau L, Lator A, Chappell-Potokar D, Denis S, et al. (2012) Influence of omega-3 fatty acid status on the way rats adapt to chronic restraint stress. PLoS One 7: e24122.
37. Kitajka K, Puskas LG, Zvara A, Hogyes E, Kitajka K, Puskas LG, Zvara A, et al. (2003) Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc Natl Acad Sci U S A 100: 11321–11326.
36. Ferraz AC, Delattre AM, Almendra MS, Linard A, et al. (2012) n-3 PUFA status affects expression of genes involved in neuroenergetics differently in the frontoparietal cortex compared to the CA1 area of the hippocampus: effect of rest and neuronal activation in the rat. Prostaglandins Leukot Essent Fatty Acids 86: 211–220.
35. Barcelo-Coblijn G, Hogyes E, Kitajka K, Puskas LG, Zvara A, et al. (2002) The role of regiospecifically unsaturated fatty acids in brain gene expression by n-3 fatty acids. Proc Natl Acad Sci U S A 99: 2619–2624.
34. Barcelo-Coblijn G, Hogyes E, Kitajka K, Puskas LG, Zvara A, et al. (2000) Maternal supply of omega-3 polyunsaturated fatty acids alter mechanisms involved in oocyte and early embryo development in the mouse. Am J Physiol Endocrinol Metab 279: E425–434.
33. Ferraz AC, Delattre AM, Almendra MS, Linard A, et al. (2012) n-3 PUFA status affects expression of genes involved in neuroenergetics differently in the frontoparietal cortex compared to the CA1 area of the hippocampus: effect of rest and neuronal activation in the rat. Prostaglandins Leukot Essent Fatty Acids 86: 211–220.
32. Lim GP, Calon F, Morihara T, Yang F, Teter B, et al. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25: 3032–3040.
31. Harbecke E, Josim M, Alesandri JM, Lallemand MS, Linard A, et al. (2012) Convergent functional genomic studies of omega-3 fatty acids in stress and following, development of hypertension. Hypertens Res 35: 381–387.
30. Chung WL, Chen JJ, Su HM (2008) Fish oil supplementation of control and (n-3) fatty acid-deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels. J Nutr 138: 1167–1171.
29. Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, et al. (2011) Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS One 6: e24051.
28. Bourre JM, Bonneil M, Dumont O, Piciotti M, Calaf R, et al. (1990) Effect of increasing amounts of dietary fish oil on brain and liver fatty composition. Biochim Biophys Acta 1043: 149–152.
27. Bourre JM, Bonneil M, Dumont O, Piciotti M, Calaf R, et al. (1990) Dietary fish oil alters the brain polyunsaturated fatty acid composition. Biochim Biophys Acta 960: 458–461.
26. Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, et al. (2011) Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood. PLoS One 6: e24051.
25. Chapple-Potokar D, Denis S, et al. (2012) Influence of omega-3 fatty acid status on the way rats adapt to chronic restraint stress. PLoS One 7: e24122.
24. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, et al. (2011) Dietary linoleic acid and polyunsaturated fatty acids in rat brain and other organs. Minimal requirements of linoleic acid. Lipids 25: 465–472.
23. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, et al. (2011) Dietary linoleic acid and polyunsaturated fatty acids in rat brain and other organs. Minimal requirements of linoleic acid. Lipids 25: 465–472.
22. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, et al. (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113: 31–33.
21. Atrash PB, Lawson S, Samogorski A, Sinclair AJ (1996) Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 Suppl: S157–161.
20. Conklin SM, Manuck SB, Yao JK, Flory JD, Bibbien JR, et al. (2007) High omega-6 and low omega-3 fatty acids are associated with depressive symptoms in hospitalized psychiatric in-patients. Psychol Med 39: 932–942.
19. Cunnane SC, Keeling PW, Thompson RP, Crawford MA (1984) Linoleic acid
18. Bourre JM, Piciotti M, Dumont O, Pascal G, Durand G (1990) Dietary linoleic acid and polyunsaturated fatty acids in rat brain and other organs. Minimal requirements of linoleic acid. Lipids 25: 465–472.
17. Cunnane SC, Keeling PW, Thompson RP, Crawford MA (1984) Linoleic acid and arachidonic acid metabolism in human peripheral blood leucocytes: comparison with the rat. Biochem J 245: 463–472.
129. Somerville MJ, Percy ME, Bergeron C, Young LK, Grüna EA, et al. (1991) Localization and quantitation of 68 kDa neurofilament and superoxide dismutase-1 mRNA in Alzheimer brains. Brain Res Mol Brain Res 9: 1–8.

130. Gulesserian T, Seidl R, Hardmeier R, Cairns N, Lubec G (2001) Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 49: 41–46.

131. Grassi-Oliveira R, Stein LM, Lopes RP, Teixeira AL, Bauer ME (2008) Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression: a preliminary report. Biol Psychiatry 64: 281–285.

132. Green EK, Raybould R, Macgregor S, Hyde S, Young AH, et al. (2006) Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry 188: 21–25.

133. Lee Y, Lim SW, Kim SY, Chung JW, Kim J, et al. (2013) Association between the BDNF Val66Met Polymorphism and Chronicity of Depression. Psychiatry Investig 10: 56–61.

134. Lin CH, Wu RM, Tai CH, Chen ML, Hu FC (2011) Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson’s disease. Parkinsonism Relat Disord 17: 84–88.

135. Looke C, Steflos K, Hoffmann N, Stramsky E, Straten G, et al. (2011) Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. Int J Neuropsychopharmacol 14: 399–404.

136. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, et al. (2008) Association of FKBp5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299: 1291–1305.

137. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, et al. (2010) Interaction of FKBp5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology 35: 1684–1692.

138. Kang JJ, Chang HC, Jeung HC, Kim SJ, An SK, et al. (2012) FKBp5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. Psychoneuroendocrinology 37: 1569–1576.

139. Minike A, Klengel T, Rubel J, Bruckl T, Pfister H, et al. (2013) Genetic variation in FKBp5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav.